|
|
|
|
| Symbol(s): |
CADX |
| Date: |
3-Jun-13 |
| Author: |
Hunter Orr |
| Contributor: |
Alpha Street Research |
| Title: |
CADX - Cadence Pharmaceuticals Inc - Downgraded to a Sell - Company Analysis and ASR Ranking Report |
| Document Size: |
9 pages |
| Price: |
$24 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $24. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| www.AlphaStreetResearch.com - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison, and our proprietary ASR Ranking indicating Buy/Sell/Hold. Cadence Pharmaceuticals Inc. is a biopharmaceutical company that develops drugs for use in hospitals. The Company produces intravenous APAP for the treatment of acute pain and fever, and omiganan for the prevention of intravascular catheter-related infections.
| | |
|
|
